EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more
EirGenix (6589) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.020x
Based on the latest financial reports, EirGenix (6589) has a cash flow conversion efficiency ratio of -0.020x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-168.94 Million) by net assets (NT$8.46 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
EirGenix - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how EirGenix's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
EirGenix Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EirGenix ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BRBI BR Partners S.A. ADSs
NASDAQ:BRBI
|
0.136x |
|
Weihai Guangtai Airport Equipment Co Ltd
SHE:002111
|
0.109x |
|
Chong Hong Construction Co Ltd
TW:5534
|
0.023x |
|
Compass Diversified Holdings
NYSE:CODI
|
0.082x |
|
American Battery Technology Company Common Stock
NASDAQ:ABAT
|
-0.082x |
|
Icahn Enterprises LP
NASDAQ:IEP
|
0.004x |
|
Songz Automobile Air Conditioning Co Ltd
SHE:002454
|
0.014x |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
0.034x |
Annual Cash Flow Conversion Efficiency for EirGenix (2017–2024)
The table below shows the annual cash flow conversion efficiency of EirGenix from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$9.26 Billion | NT$-311.44 Million | -0.034x | +60.29% |
| 2023-12-31 | NT$10.02 Billion | NT$-848.56 Million | -0.085x | -513.43% |
| 2022-12-31 | NT$10.68 Billion | NT$-147.52 Million | -0.014x | -381.65% |
| 2021-12-31 | NT$10.43 Billion | NT$-29.90 Million | -0.003x | +98.70% |
| 2020-12-31 | NT$1.91 Billion | NT$-419.26 Million | -0.220x | +7.36% |
| 2019-12-31 | NT$3.30 Billion | NT$-784.07 Million | -0.237x | -6.49% |
| 2018-12-31 | NT$2.09 Billion | NT$-465.61 Million | -0.223x | -34.68% |
| 2017-12-31 | NT$1.14 Billion | NT$-189.57 Million | -0.166x | -- |